Juan I. Luengo

3.1k citations

58 papers · 1.5k indexed · h-index 23

Co-authors: Masato Koreeda Dennis A. Holt John G. Gleason Kevin J. Duffy Stephen G. Miller Jon Rosen Connie L. Erickson‐Miller Evelyne Delorme
Topics: Bioactive Compounds and Antitumor Agents (6 papers)Biochemical and Molecular Research (6 papers)PI3K/AKT/mTOR signaling in cancer (6 papers)
Cited by: Hematology Organic Chemistry Toxicology
Journals: Science Journal of the American Chemical Society Journal of Biological Chemistry
Partner nations: United States United Kingdom China

In The Last Decade

Juan I. Luengo

58 papers receiving 1.5k citations

Peers

Countries citing papers authored by Juan I. Luengo

Since Specialization

Citations

This map shows the geographic impact of Juan I. Luengo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Juan I. Luengo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Juan I. Luengo more than expected).

Fields of papers citing papers by Juan I. Luengo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Juan I. Luengo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Juan I. Luengo. The network helps show where Juan I. Luengo may publish in the future.

Co-authorship network of co-authors of Juan I. Luengo

This figure shows the co-authorship network connecting the top 25 collaborators of Juan I. Luengo. A scholar is included among the top collaborators of Juan I. Luengo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Juan I. Luengo. Juan I. Luengo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract LB163: Discovery and characterization of QTX3544, a potent, selective, and orally bioavailable allosteric G12V preferring multi KRAS inhibitor 2024 ·Cancer Research ·(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Greg Lee,(unknown),(unknown),(unknown),(unknown),(unknown),Juan I. Luengo,(unknown),(unknown),Hong Lin	2
2	Abstract LB_C09: QTX3034, a potent and selective multi-KRAS inhibitor, synergizes with EGFR inhibitors and enhances anti-tumor activity 2023 ·Molecular Cancer Therapeutics ·(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Christopher C. Pan,Juan I. Luengo,(unknown),Hong Lin	2
3	Abstract LB320: Discovery and characterization of QTX3034, a potent, selective, and orally bioavailable allosteric KRAS inhibitor 2023 ·Cancer Research ·(unknown),(unknown),(unknown),(unknown),(unknown),Greg Lee,(unknown),(unknown),(unknown),Juan I. Luengo,(unknown),Hong Lin	7
4	Abstract LB321: Discovery and characterization of QTX3046, a potent, selective, and orally bioavailable non-covalent KRASG12D inhibitor 2023 ·Cancer Research ·(unknown),(unknown),(unknown),(unknown),(unknown),Greg Lee,(unknown),(unknown),(unknown),Juan I. Luengo,Hong Lin,(unknown)	8
5	Exploiting binding-site arginines in drug design: Recent examples 2020 ·Bioorganic & Medicinal Chemistry Letters ·Honghuang Lin,Juan I. Luengo	4
6	Nucleoside protein arginine methyltransferase 5 (PRMT5) inhibitors 2019 ·Bioorganic & Medicinal Chemistry Letters ·Hong Lin,Juan I. Luengo	37
7	Synthesis and structure–activity relationships of 1,2,4-triazolo[1,5-a]pyrimidin-7(3H)-ones as novel series of potent β isoform selective phosphatidylinositol 3-kinase inhibitors 2012 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),Karl F. Erhard,Mary Ann Hardwicke,Hong Lin,Jeanelle McSurdy-Freed,Ramona Plant,Kaushik Raha,Cynthia M. Rominger,Michael D. Schaber,Michael D. Spengler,Michael L. Moore,Hongyi Yu,Juan I. Luengo,Rosanna Tedesco,Ralph A. Rivero	42
8	Synthesis and structure–activity relationships of imidazo[1,2-a]pyrimidin-5(1H)-ones as a novel series of beta isoform selective phosphatidylinositol 3-kinase inhibitors 2012 ·Bioorganic & Medicinal Chemistry Letters ·Hong Lin,Karl F. Erhard,Mary Ann Hardwicke,Juan I. Luengo,(unknown),Jeanelle McSurdy-Freed,Ramona Plant,Kaushik Raha,Cynthia M. Rominger,(unknown),Michael D. Schaber,Mark J. Schulz,Michael D. Spengler,Rosanna Tedesco,(unknown),Jin Zeng,Ralph A. Rivero	31
9	Molecular clinical safety intelligence: a system for bridging clinically focused safety knowledge to early-stage drug discovery – the GSK experience 2011 ·Drug Discovery Today ·Dana E. Vanderwall,Nancy Yuen,(unknown),James M. Bailey,David Fram,Darren V. S. Green,Stephen D. Pickett,Giovanni Vitulli,Juan I. Luengo,June S. Almenoff	8
10	Unusual ligand-dependent chemoselective Suzuki–Miyaura cross-coupling reactions of 3-bromo-4-trifloyl-thiophenes 2011 ·Tetrahedron Letters ·Jizhou Wang,Mark A. Seefeld,Juan I. Luengo	14
11	2,3,5-Trisubstituted pyridines as selective AKT inhibitors—Part I: Substitution at 2-position of the core pyridine for ROCK1 selectivity 2009 ·Bioorganic & Medicinal Chemistry Letters ·Hong Lin,Dennis S. Yamashita,Jin Zeng,(unknown),Wenyong Wang,(unknown),Juan I. Luengo,Nelson Rhodes,Victoria B. Knick,Anthony E. Choudhry,Zhihong Lai,Elisabeth A. Minthorn,Susan L. Strum,Edgar R. Wood,P.A. Elkins,N.O. Concha,Dirk A. Heerding	11
12	Discovery of 5-pyrrolopyridinyl-2-thiophenecarboxamides as potent AKT kinase inhibitors 2009 ·Bioorganic & Medicinal Chemistry Letters ·Mark A. Seefeld,Meagan B. Rouse,(unknown),(unknown),Jizhou Wang,Dennis S. Yamashita,Juan I. Luengo,ShuYun Zhang,Elisabeth A. Minthorn,N.O. Concha,Dirk A. Heerding	21
13	2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles 2009 ·Bioorganic & Medicinal Chemistry Letters ·Hong Lin,Dennis S. Yamashita,Jin Zeng,(unknown),Sharad K. Verma,Juan I. Luengo,Nelson Rhodes,Shuyun Zhang,Kimberly A. Robell,Anthony E. Choudhry,Zhihong Lai,Rakesh Kumar,Elisabeth A. Minthorn,Kristin K. Brown,Dirk A. Heerding	8
14	Species specificity and receptor domain interaction of a small molecule Tpo receptor agonist, SB-497115 2005 ·Cancer Research ·Connie L. Erickson‐Miller,Shin‐Shay Tian,Christopher B. Hopson,(unknown),Maya Iskandar,Leslie Giampa,Juan I. Luengo,Kevin J. Duffy,Susan B. Dillon,Stephen G. Miller,Jon Rosen,Peter Lamb,Timothy K. Hart,Krishna K. Murthy,Teresa S. Sellers	2
15	Biological Activity and Selectivity for Tpo Receptor of the Orally Bioavailable, Small Molecule Tpo Receptor Agonist, SB-497115. 2004 ·Blood ·Connie L. Erickson‐Miller,(unknown),Leslie Giampa,Christopher B. Hopson,Elizabeth I. Valoret,Shin‐Shay Tian,Stephen G. Miller,Richard M. Keenan,Jon Rosen,Susan B. Dillon,Kevin J. Duffy,Peter Lamb,Juan I. Luengo	27
16	Identification of a Pharmacophore for Thrombopoietic Activity of Small, Non-Peptidyl Molecules. 2. Rational Design of Naphtho[1,2-d]imidazole Thrombopoietin Mimics 2002 ·Journal of Medicinal Chemistry ·Kevin J. Duffy,Alan T. Price,Evelyne Delorme,Susan B. Dillon,Céline Duquenne,Connie L. Erickson‐Miller,Leslie Giampa,Yifang Huang,Richard M. Keenan,Peter Lamb,Nannan Liu,Stephen G. Miller,Jon Rosen,Anthony N. Shaw,(unknown),Kenneth J. Wiggall,Lihua Zhang,Juan I. Luengo	44
17	Pharmacologic Characterization of the Novel, Orally Available Endothelin-A-Selective Antagonist SB 247083 1998 ·Journal of Cardiovascular Pharmacology ·Stephen A. Douglas,Ponnal Nambi,Miklos Gellai,Juan I. Luengo,Jia‐Ning Xiang,David P. Brooks,Robert Ruffolo,John D. Elliott,Eliot H. Ohlstein	5
18	Plasma- and Cerebrospinal Fluid-Immunoreactive Endothelin-1: Effects of Nonpeptide Endothelin Receptor Antagonists with Diverse Affinity Profiles for Endothelin-A and Endothelin-B Receptors 1998 ·Journal of Cardiovascular Pharmacology ·Robert N. Willette,Charles F. Sauermelch,Barbara L. Storer,(unknown),Juan I. Luengo,Jia‐Ning Xiang,John D. Elliott,Eliot H. Ohlstein	18
19	Benzophenone- and Indolecarboxylic Acids: Potent Type-2 Specific Inhibitors of Human Steroid 5.alpha.-Reductase 1995 ·Journal of Medicinal Chemistry ·Dennis A. Holt,Dennis S. Yamashita,(unknown),Juan I. Luengo,Andrew D. Abell,Derk J. Bergsma,Martín Brandt,Mark A. Levy	30
20	Structure-activity studies of synthetic FKBP ligands as peptidyl-prolyl isomerase inhibitors 1994 ·Bioorganic & Medicinal Chemistry Letters ·Dennis A. Holt,(unknown),Hye-Ja Oh,(unknown),Leonard W. Rozamus,(unknown),Karl F. Erhard,(unknown),Mark A. Levy,Martín Brandt,Mary J. Bossard,Juan I. Luengo	28

About Juan I. Luengo

Juan I. Luengo is a scholar working on Toxicology, Organic Chemistry and Molecular Biology, having authored 58 papers that have together received 1.5k indexed citations. Recurring topics across this work include Bioactive Compounds and Antitumor Agents (6 papers), Biochemical and Molecular Research (6 papers) and PI3K/AKT/mTOR signaling in cancer (6 papers). The work is most often cited by research in Hematology (341 citations), Organic Chemistry (476 citations) and Toxicology (37 citations). Juan I. Luengo has collaborated with scholars based in United States, United Kingdom and China. Frequent co-authors include Masato Koreeda, Dennis A. Holt, John G. Gleason, Kevin J. Duffy, Stephen G. Miller, Jon Rosen, Connie L. Erickson‐Miller, Evelyne Delorme, Hong Lin and Shin‐Shay Tian. Their work appears in journals such as Science, Journal of the American Chemical Society and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact